Global drugmakers may consider cutting prices to gain inclusion in Russian public procurement
The Russian government will revise plans for the purchase of some of the most expensive drugs for state needs this year due to the lack of funds in the state budget, according to some sources close to the federal government and local media, reports The Pharma Letter’s local correspondent.
As part of these plans, the government will probably reduce the volume of purchases of Hemlibra (emicizumab), which is produced by Swiss pharma giant Roche (ROG: SIX) for patients with hemophilia.
It is planned procurements of the drug will be included in the existing state program of high-cost nosologies, the total value of which amounted to 45.1 billion roubles ($576 million) in 2019, and allowed purchases of 14 various drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze